These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28272000)

  • 1. Study of Serum Carcinoembryonic Antigen's Profile for Breast Cancer in Western Algeria: 100 cases.
    Tahari Z; Medjdoub A; Sahraoui T; Belhabri L; El Kebir FZ
    Gulf J Oncolog; 2017 Jan; 1(23):33-36. PubMed ID: 28272000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
    Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
    Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters.
    Uygur MM; Gümüş M
    Cancer Treat Res Commun; 2021; 28():100402. PubMed ID: 34082362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.
    Fu Y; Li H
    Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer.
    Pathak KA; Khanna R; Khanna HD; Khanna S; Gupta S; Khanna NN
    J Postgrad Med; 1996; 42(3):68-71. PubMed ID: 9715319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
    Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
    J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
    Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
    Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
    Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
    Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tumor markers in southern Indian breast cancer patients.
    Porika M; Malotu N; Veldandi UK; Yadala N; Abbagani S
    Asian Pac J Cancer Prev; 2010; 11(1):157-9. PubMed ID: 20593949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.